Rheumatology

Article	Citations
Lupus nephritis: clinical presentations and outcomes in the 21st century	100
Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series	99
Osteosarcopenia: where osteoporosis and sarcopenia collide	96
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study	96
Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark	93
COVID-19 vaccination and antirheumatic therapy	88
The genetics of rheumatoid arthritis	83
Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors	82
A roadmap to target interleukin-6 in osteoarthritis	76
Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs	75
Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease	74
Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis	73
A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies	70
Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis	68
VEXAS syndrome in a woman	67
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients	64
Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis	63
The safety of JAK-1 inhibitors	63
Genetics and epigenetics in primary Sjögren’s syndrome	62
Rituximab in the treatment of systemic sclerosis–related interstitial lung disease: a systematic review and meta-analysis	61
Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease	58
Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis	58
Sex and gender differences in axial spondyloarthritis: myths and truths	57
Is fibromyalgia associated with a unique cytokine profile? A systematic review and meta-analysis	54
Telemedicine in rheumatology: a reliable approach beyond the pandemic	54

Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls	54
Classifying and diagnosing systemic lupus erythematosus in the 21st century	53
Global, regional, and national burden of other musculoskeletal disorders 1990–2017: results from the Global Burden of Disease Study 2017	53
The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?	53
Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis	52
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19	52
Treatment of Sjögren’s syndrome: current therapy and future directions	52
Correlation between pain severity and levels of anxiety and depression in osteoarthritis patients: a systematic review and meta-analysis	51
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus	50
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study	47
Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes	46
Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease	46
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials	45
Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study	45
Atypical splice-site mutations causing VEXAS syndrome	44
A case of psoriatic arthritis triggered by SARS-CoV-2 infection	44
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis	43
Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility	43
Telemedicine in rheumatology: a mixed methods study exploring acceptability, preferences and experiences among patients and clinicians	43
Association between environmental air pollution and rheumatoid arthritis flares	42
Prevalence, incidence and cause-specific mortality of rheumatoid arthritis–associated interstitial lung disease among older rheumatoid arthritis patients	42
Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study	42
Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus	41
An association between chronic widespread pain and the gut microbiome	41
The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis	41
Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice	41
The cut-off values for the intima–media complex thickness assessed by colour Doppler sonography in seven cranial and aortic arch arteries	41
Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic	41
Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties	41
Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2)	41
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study	41
Temporal relationship between osteoarthritis and comorbidities: a combined case control and cohort study in the UK primary care setting	41
Rheumatoid arthritis related interstitial lung disease – improving outcomes over 25 years: a large multicentre UK study	40
British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy	40
Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccin	40
VEXAS syndrome: still expanding the clinical phenotype	40
Glycine increased ferroptosis via SAM-mediated GPX4 promoter methylation in rheumatoid arthritis	39
Circulating adiponectin levels and systemic lupus erythematosus: a two-sample Mendelian randomization study	38
Treatment strategies in axial spondyloarthritis: what, when and how?	38
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis	38
Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions	38
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries	38
EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies	38
Rhabdomyolysis as the main manifestation of coronavirus disease 2019	38
Acute exacerbation of rheumatoid arthritis–associated interstitial lung disease: clinical features and prognosis	38
VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy	37
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial	37
IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts	37
COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries	36
Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study	36

Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy	36
Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis	36
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids	35
Whole-body MRI in the diagnosis of paediatric CNO/CRMO	35
Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection	35
COVID-19 and myositis – unique challenges for patients	35
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort	34
Socioeconomic status and occurrence of chronic pain: a meta-analysis	34
Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis	34
Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy	34
Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis	34
Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis	33
New biomarkers in SLE: from bench to bedside	33
IL-37 inhibits M1-like macrophage activation to ameliorate temporomandibular joint inflammation through the NLRP3 pathway	33
Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma	33
Childhood Sjögren syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria	33
Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sjögren’s syndrome	33
Tele-rheumatology for overcoming socioeconomic barriers to healthcare in resource constrained settings: lessons from COVID-19 pandemic	33
Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience	32
Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study	32
Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease	32
Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database	32
Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study	32
A case of VEXAS syndrome manifesting as Kikuchi-Fujimoto disease, relapsing polychondritis, venous thromboembolism and macrocytic anaemia	32
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice	32
A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition	32
Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study	31
The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study	31
The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance	31
Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population	31
Retinal microcirculation abnormalities in patients with systemic sclerosis: an explorative optical coherence tomography angiography study	30
All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study	30
Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis	30
JAK1: Number one in the family; number one in inflammation?	29
The impact of education inequality on rheumatoid arthritis risk is mediated by smoking and body mass index: Mendelian randomization study	29
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications	29
Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash	29
Systemic autoimmune disease as a cause of death: mortality burden and comorbidities	29
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice	29
Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre	28
Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs	28
The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease	28
Axial spondyloarthritis 10 years on: still looking for the lost tribe	28
Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach	28
Towards sex-specific osteoarthritis risk models: evaluation of risk factors for knee osteoarthritis in males and females	28
A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis	28
All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study	28
Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica	28
Comorbidities (excluding lymphoma) in Sjögren’s syndrome	28
Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis	27
Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study	27
P105 Prevalence and associated factors of musculoskeletal joint disease in the community setting in Hai district, northern Tanzania	27
PKM2-dependent glycolysis promotes skeletal muscle cell pyroptosis by activating the NLRP3 inflammasome in dermatomyositis/polymyositis	27
Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases	27
A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment	27
JAK1 inhibition and inflammatory bowel disease	27
Childhood-onset of primary Sjögren’s syndrome: phenotypic characterization at diagnosis of 158 children	26
The iCanCope pain self-management application for adolescents with juvenile idiopathic arthritis: a pilot randomized controlled trial	26
Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis	26
Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis	26
Femoral vein wall thickness measurement: A new diagnostic tool for Behçet’s disease	26
Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study	26
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome	26
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study	26
Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway	26
An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis	26
Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis	26
Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis	26
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parall	26
Frugoside delays osteoarthritis progression via inhibiting miR-155-modulated synovial macrophage M1 polarization	26
Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review	25
Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis	25
Tofacitinib in patients with refractory Takayasu’s arteritis	25
A systematic review and meta-analysis of the incidence rate of Takayasu arteritis	25
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension	25
Patient-based reliability of the Outcome Measures in Rheumatology (OMERACT) ultrasound scoring system for salivary gland assessment in patients with Sjögren’s syndrome	25
Causal relationship of serum nutritional factors with osteoarthritis: a Mendelian randomization study	25
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study	25
The patient’s perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?	25
Treatment targets in SLE: remission and low disease activity state	25

Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study	25
Neutrophil extracellular traps mediate joint hyperalgesia induced by immune inflammation	25
Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA	24
Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series	24
Joint anatomy in axial spondyloarthritis: strong associations between sacroiliac joint form variation and symptomatic disease	24
Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants	24
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients	24
Current and emerging biological therapy in adult-onset Still’s disease	24
Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases	24
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review	24
Long-term outcome after perineural injection with 5% dextrose for carpal tunnel syndrome: a retrospective follow-up study	23
Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America	23
New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study	23
High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care centre in northern India	23
Dissecting the clinical heterogeneity of adult-onset Still’s disease: results from a multi-dimensional characterization and stratification	23
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	23
Incidence and prevalence of juvenile idiopathic arthritis in the United Kingdom, 2000–2018: results from the Clinical Practice Research Datalink	23
Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study	23
Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis	23
Glucocorticoid use is associated with an increased risk of hypertension	23
Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS	23
Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease	23
Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs—a Swedish cohort study of risks by time, drug and lymphoma subtype	23
Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study	22
Targeted photodynamic therapy selectively kills activated fibroblasts in experimental arthritis	22
Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout	22
Behçet’s-like adverse event or inaugural Behçet’s disease after SARS-CoV-2 mRNA-1273 vaccination?	22
Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?—observations from the UK JSLE Cohort Study	22
Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis	22
Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis	22
Are neutrophil extracellular traps the link for the cross-talk between periodontitis and rheumatoid arthritis physiopathology?	22
Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments	22
Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility	22
Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients	22
A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever	22
Elevated circulating pro-inflammatory low-density granulocytes in adult-onset Still’s disease	22
Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis	22
Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)	21
Prevalence of anxiety and depression in patients with rheumatoid arthritis before and during the COVID-19 pandemic	21
Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes	21
Deep learning algorithms for magnetic resonance imaging of inflammatory sacroiliitis in axial spondyloarthritis	21
Clonal haematopoiesis is increased in early onset in systemic sclerosis	21
LncRNA-H19 silencing suppresses synoviocytes proliferation and attenuates collagen-induced arthritis progression by modulating miR-124a	21
Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response	21
COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis	21
The impact of smoking on prevalence of psoriasis and psoriatic arthritis	21
A new diagnosis of systemic capillary leak syndrome in a patient with COVID-19	21
Multi-energy photon-counting computed tomography versus other clinical imaging techniques for the identification of articular calcium crystal deposition	21
Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search	21
Identification and characterization of two consistent osteoarthritis subtypes by transcriptome and clinical data integration	21
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)	21
Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic	21
Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study	21
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study	21
A dysregulated interleukin-18–interferon-γ–CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis	21
Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis	21
Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis	21
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes	21
Vitamin D receptor gene polymorphisms and osteoarthritis: a meta-analysis	20
Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study	20
Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus	20
The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease	20
Non-radiographic versus radiographic axSpA: what’s in a name?	20
Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma	20
Consensus-based recommendations for the management of juvenile systemic sclerosis	20
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis	20
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study	20
An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus	20
Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren’s syndrome: results from a harmonized dataset (1981–2021)	20
Ultrasound for the diagnosis of gout—the value of gout lesions as defined by the Outcome Measures in Rheumatology ultrasound group	20
Early recognition of patients with axial spondyloarthritis—evaluation of referral strategies in primary care	20
Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study	20
Defining cardiac involvement in idiopathic inflammatory myopathies: a systematic review	20
STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis	20
Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual	20
Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia	20
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study	20
Feasibility of online home spirometry in systemic sclerosis–associated interstitial lung disease: a pilot study	20
US rheumatologists’ beliefs and knowledge about biosimilars: a survey	20
P208 A retrospective survey of arthritis among inpatients at a consultant hospital in Northern Tanzania from 2017 to 2019	20
Endotypes of primary osteoarthritis identified by plasma metabolomics analysis	20
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data	20
The impact of COVID-19 on rheumatology practice across Africa	20
Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to anakinra	20
Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)	20
Survival and associated comorbidities in inclusion body myositis	20
Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis	19
Potential efficacy of dendritic cell immunomodulation in the treatment of osteoarthritis	19
Fully automated opportunistic screening of vertebral fractures and osteoporosis on more than 150 000 routine computed tomography scans	19
Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma	19
Quantitative nailfold capillaroscopy—update and possible next steps	19
Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus	19
Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience	19
Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study	19
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies	19